Tagged: 2020

Monthly Research Review: Jaunary 2020

 

At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020.

The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and Review articles/videos

 


So, what happened during January 2020?

In world news:

January 6th – From the only in London files – this was “No Trousers Tube Ride 2020” day (don’t ask me to explain… I wouldn’t know where to begin – click here to read more about this).

January 23rd – The Chinese city of Wuhan was placed under quarantine, in which all public transport in and out of the city was suspended in efforts to control the spread of a new coronavirus, designated 2019-nCoV.

January 26th – In the build up to BREXIT, the UK presented the new 50 pence coin… with a gramatical error. Three million coins bearing the slogan “Peace, prosperity and friendship with all nations” are due to enter circulation from 31 January (Click here to read more about this).

January 30th – The Daniel K Inouye Solar Telescope on Hawaii released new footage of the surface of the sun showing features as small as 30km across.(Click here to read more about this).

 

31st January – As the bush fires in Australia have continued over January, a state of emergency was declared in the Canberra region, with fires reaching suburbs just south of the capital (Click here to read more about this).

 

In the world of Parkinson’s research, a great deal of new research and news was reported:

In January 2020, there were 849 research articles added to the Pubmed website with the tag word “Parkinson’s” attached (8195 for all of 2019 – updated number). In addition, there was a wave to news reports regarding various other bits of Parkinson’s research activity (clinical trials, etc).

The top 5 pieces of Parkinson’s news

Continue reading

2020 wish list

 

Here at the Science of Parkinson’s, we don’t like making predictions – that’s a mug’s game.

We would rather explore interesting ideas based around what we hope to see happen in 2020 – discussing different ways and means by which they could occur – in the hope that some one will pick up the ball and run with it (ideally, they already have the ball and we are as usual naively unaware).

In today’s post, we will outline the SoPD wish list for 2020.

 


Source: Amazon

In his excellent biography on Leonado Da Vinci, author Walter Isaacson drops a beautiful hook in the middle of the book to compel the reader on.

As you may be aware, Da Vinci kept lots of journals throughout his life, and he was constantly making drawings and notes. On almost every page, however, he also made list of things to do, and these list suggest an incredibly curious mind.

Isaacson listed a few examples, including:

“Get the master of arithmetic to show you how to square a triangle… Ask Giannino the Bombardier about how the tower of Ferrara is walled… Ask Benedetto Protinari by what means they walk on ice in Flanders… Get a master of hydraulics to tell you how to repair a lock, canal and mill in the Lombard manner…”

Source: Kottke

But in the middle of the book, Isaacson gives the reader his personal favourite:

“Describe the tongue of the woodpecker”

And then he continues:

“‘Describe the tongue of the woodpecker,’ he instructs himself. Who on earth would decide one day, for no apparent reason, that he wanted to know what the tongue of a woodpecker looks like? How would you even find out? It’s not information Leonardo needed to paint a picture or even to understand the flight of birds”

Wait. What? Woodpeckers have tongues?!?

Continue reading

The road ahead: 2020

Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition.

At the start of each year, it is a useful practise to layout what is planned and what we will be looking for over the next 12 months. Obviously, where 2020 will actually end is unpredictable, but an outline of what is scheduled over the next year will hopefully provide us with a useful resource for better managing expectations.

In this post, I will try to lay out some of what 2020 holds for us with regards to clinical research focused on disease modification for Parkinson’s.


BP

Lord Robert Baden-Powell. Source: Utahscouts

My old scout master once looked around our horse shoe, making eye contact with each of us, before asking the question:

“When did Noah build the ark?”

My fellow scouts and I looked at each other – confused. Did he want an exact date?!?

The scout master waited a moment for one of us to offer up some idiotic attempt at an answer – thankfully no one did – before he solemnly said:

“Before the rain”

It was one of those childhood moments that made little sense at the time, but comes back to haunt you as an adult when you are looking at what the future may hold and trying to plan for it.

# # # # # # # # # # #

Today’s post is our annual horizon scanning effort, where we lay out what is on the cards for the next 12 months with regards to clinical research focused on disease modification in Parkinson’s.

Source: Rand

We will also briefly mention other bits and pieces of preclinical work that we are keeping an eye on for any news of development.

To be clear, this post is NOT intended to be an exercise in the reading of tea leaves – no predictions will be made here. Nor is this a definitive or exhaustive guide of what the next year holds for disease modification research (if you see anything important that I have missed – please contact me). And it should certainly not be assumed that any of the treatments mentioned below are going to be silver bullets or magical elixirs that are going to “cure” the condition.

In the introduction to last year’s outlook, I wrote of the dangers of having expectations (Click here to read that post). I am not going to repeat that intro here, but that the same message applies as we look ahead to what 2020 holds.

Source: Unitystone

In fact, it probably applies even more for 2020, than it did for 2019.

2020 is going to be a busy year for Parkinson’s research, and I am genuinely concerned that posts like this are only going to raise expectations. My hope is that a better understanding of where things currently are and what is scheduled for the next 12 months will help in better managing those expectations. Please understand that there is still a long way to go for all of these experimental therapies.

All of that said, let’s begin:

Continue reading

The road ahead: Parkinson’s research in 2018

The great ice hockey player Wayne Gretzky once said “A good hockey player plays where the puck is. A great hockey player plays where the puck is going to be” (the original quote actually came from his father, Walter). 

At the start of each year, it is a useful practise to layout what is planned for the next 12 months. This can help us better anticipate where ‘the puck’ will be, and allow us to prepare for things further ahead.

2017 was an incredible year for Parkinson’s research, and there is a lot already in place to suggest that 2018 is going to be just as good (if not better).

In this post, we will lay out what we can expect over the next 12 months with regards to the Parkinson’s-related clinical trials research of new therapies.


Charlie Munger (left) and Warren Buffett. Source: Youtube

Many readers will be familiar with the name Warren Buffett.

The charming, folksy “Oracle of Omaha” is one of the wealthiest men in the world. And he is well known for his witticisms about investing, business and life in general.

Warren Buffett. Source: Quickmeme

He regularly provides great one liners like:

“We look for three things [in good business leaders]: intelligence, energy, and integrity. If they don’t have the latter, then you should hope they don’t have the first two either. If someone doesn’t have integrity, then you want them to be dumb and lazy”

“Work for an organisation of people you admire, because it will turn you on. I always worry about people who say, ‘I’m going to do this for ten years; and if I really don’t like it very much, then I’ll do something else….’ That’s a little like saving up sex for your old age. Not a very good idea”

“Choosing your heroes is very important. Associate well, marry up and hope you find someone who doesn’t mind marrying down. It was a huge help to me”

Mr Buffett is wise and a very likeable chap.

Few people, however, are familiar with his business partner, Charlie Munger. And Charlie is my favourite of the pair.

Continue reading